Godlike Productions - Reply to Thread

Users Online Now: 2,233 (Who's On?)	Visitors Today: 1,051,315
Pageviews Today: 1,754,166	Threads Today: 706	Posts Today: 12,637
05:18 PM

REPLY TO THREAD

Subject Ebola patent info and ZMap company info. (Very interesting)

User Name

Font color: Font:

In accordance with industry accepted best practices we ask that users limit their copy / paste of copyrighted material to the relevant portions of the article you wish to discuss and no more than 50% of the source material, provide a link back to the original article and provide your original comments / criticism in your post with the article.

[quote:~KPM~:MV8yNjExNTM0XzQ1NjYzNzMwX0U0OEQ5OURE]
[quote:Anonymous Coward 61126166:MV8yNjExNTM0XzQ1NjYzMzg4X0VBQjYwRjg=]
[quote:~KPM~:MV8yNjExNTM0XzQ1NjU5MTc1X0RDMUI0RTUw]
So according to the article protocol was broken and they used the secret serum that was slated for testing in 2015?

It had not even gone through phase one and they use it?

WTF IS GOING ON?

Is this why and who brought Ebola here?

Ebola crops up unexpectedly in a new spot, two Americans flown home get a serum that has not even been tested?

[b]Under the US Food and Drug Administration’s so-called ‘animal rule,’ these experimental treatments for Ebola—for which it would be impractical or unethical to demonstrate efficacy in humans—can be licensed for human use provided that phase 1 trials demonstrate that they are safe in humans.

However, aside from Tekmira’s RNAi therapy for Ebola, the phase 1 trial of which is slated to wrap up by the middle of this year, none of these treatments appears likely to clear human safety tests any time soon. “It’s always difficult to see an ongoing outbreak, and we haven’t had time to cross all those tests for licensure,” Kobinger says. But, he adds, “we’re really hoping that we’ll have something in place for the next outbreak.”[/b]

http://blogs.nature.com/spoonful/2014/04/ebola-outbreak-in-west-africa-lends-urgency-to-recently-funded-research.html
[/quote]

Yeah why use this serum and not the Tekmira one which is further along in trials?

My head is spinning trying to make sense of all this.
[/quote]

Mine too!

The more we dig the more we find.....we will never be ahead of things because we only have the benefit of hindsight.....

In the case of Ebola hindsight is too late.....
[/quote]

Original Message I always say to follow the money. Here is what I have found so far on the company Mapp Biopharmaceutical, Inc.

Toronto, ON - Today Defyrus announced an exclusive, worldwide license to their Ebola therapeutic monoclonal antibody (mAb) patent portfolio to Leaf Biopharmaceutical Inc. of San Diego, CA. This license expands the commercial relationship between LeafBio and Defyrus who have been actively collaborating to drive the commercialization of mAb-based Ebola therapies.

LeafBio, the commercialization partner of Mapp Biopharmaceutical, had been developing proprietary Ebola-specific antibody drug MB-003 in collaboration with the National Institutes of Health and the Defense Threat Reduction Agency (DTRA). The licensing of Defyrus’ ZMAb antibody portfolio, pioneered at the Public Health Agency of Canada (PHAC) and licensed earlier to Defyrus, consolidates the intellectual property of a superior combination mAb drug – termed ZMappTM - which is composed of the best mAbs of MB-003 and ZMAb ( [link to www.defyrus.com] July152014-ZMAb-license.pdf)

Defyrus
Dr. Jeffrey D. Turner President & CEO Tel: (613) 674-1138 [email protected]

Dr. Larry Zeitlin President Tel: (800) 372-2176 [email protected]

About Defyrus
Defyrus is a Canadian private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, Asia and Canada to develop broad spectrum anti-viral drugs, MAbs and vaccines as medical countermeasures to viral and bacterial infectious diseases. www.defyrus.com
About Mapp and Leaf Biopharmaceutical
Mapp Biopharmaceutical develops novel biopharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. As these products transition to clinical evaluation, Leaf Biopharmaceutical assumes ownership and commercialization responsibilities.
www.mappbio.com, www.leafbio.com

According to patent # CA2741523 A1 and US 20120251502 ( [link to www.collectiveip.com (secure)] There are 5 people that submitted for the ebola patent.

1) Jonathan S. Towner - Virologist at Centers for Disease Control and Prevention
[link to www.linkedin.com]

2) Dr. Stuart Nichol - Dr. Stuart Nichol is chief of the Molecular Biology Section, Special Pathogens Branch, at the Centers for Disease Control (CDC) in Atlanta, Georgia. He is also a professor of microbiology and immunology at Emory University. - [link to www.pbs.org]

3) James A. Comer - Microbiologist Dr. James (“Andy”) Comer ( [link to blogs.cdc.gov]

4) Thomas G Ksiazek, DVM, PhD
Epidemiology/ecology and laboratory diagnosis of hemorrhagic fevers and arthropod-borne viral diseases. More specifically, these include the mechanisms of transmission from reservoir zoonotic hosts to humans as well as transmission of the viral hemorrhagic fever viruses from case to case, particularly in health care settings. Of recent interest has been the persistence of the hemorrhagic fever viruses in reservoir populations and individual animals. The reservoir host(s) of the filoviruses has been a particular interest over the past 20 years, and in the last five years or so has focused on megachiropterans.

Also of personal interest is the area of high containment operations and operational biosafety. My goal is to facilitate a high containment laboratory environment that promotes excellence in science while maintaining the necessary high standards of safety and security necessary to work with high consequence pathogens in today's world ( [link to www.utmb.edu]

5) Pierre E. Rollin - Viral Special Pathogens Branch (VSPB), Division of High Consequence Pathogens and Pathology (DHCPP), National Center for Emerging Zoonotic Infectious Diseases (NCEZID) , and Centers for Disease Control and Prevention (CDC) -( [link to apps.who.int]

Human ebola virus species and compositions and methods thereof
WO 2010048615 A3
ABSTRACT
Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

Applicant -The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention ( [link to www.google.com (secure)]

We need to see if any of these people have stock in one of the companies that are trying to produce a vaccine.

We need to list all the companies trying to manufacture a vaccine.

Mapp Biopharmaceutical that created ZMapp.

Here are some of the employee's names that run Map.

Name Title
Kevin Whaley Chief Executive Officer

Larry Zeitlin President

Paul Donovan Director

[link to companies.findthebest.com] - They have been registered since 2003

This listing is for Mapp Biopharmaceutical, Inc's Single Location in San Diego, CA. The company primarily operates in the Research and Development in the Physical, Engineering, and Life Sciences Companies industry.

Mapp Biopharmaceutical, Inc:

Was founded in 2003 and is Privately held.
Has $810,000 in estimated annual revenue.
Employs 8 people.
Has 8 employees located here at the Single Location.

Here are all the government contracts that Mapp is currently involved in. We need to see if any of the people that owns the patent are part of this company.

[link to www.fpds.gov (secure)]

Award ID (Mod#):
HDTRA113C0018 ( 0 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEFENSE THREAT REDUCTION AGENCY (DTRA)
Date Signed: February 19, 2013 Action Obligation: $1,747,135.5
Referenced IDV: Contracting Office: DEFENSE THREAT REDUCTION AGENCY
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) ( AN12 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Award ID (Mod#):
HDTRA113C0018 ( P00001 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEFENSE THREAT REDUCTION AGENCY (DTRA)
Date Signed: July 24, 2013 Action Obligation: $583,690.5
Referenced IDV: Contracting Office: DEFENSE THREAT REDUCTION AGENCY
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) ( AN12 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Award ID (Mod#):
HDTRA113C0018 ( P00002 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEFENSE THREAT REDUCTION AGENCY (DTRA)
Date Signed: February 20, 2014 Action Obligation: $2,864,542
Referenced IDV: Contracting Office: DEFENSE THREAT REDUCTION AGENCY
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): R&D- MEDICAL: BIOMEDICAL (APPLIED RESEARCH/EXPLORATORY DEVELOPMENT) ( AN12 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Award ID (Mod#):
W81XWH12C0144 ( 0 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEPT OF THE ARMY
Date Signed: June 01, 2012 Action Obligation: $88,540
Referenced IDV: Contracting Office: W4PZ USA MED RSCH ACQUIS ACT
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): SUPPORT- PROFESSIONAL: OTHER ( R499 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Award ID (Mod#):
W81XWH12C0144 ( P00001 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEPT OF THE ARMY
Date Signed: May 28, 2013 Action Obligation: $0
Referenced IDV: Contracting Office: W4PZ USA MED RSCH ACQUIS ACT
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): SUPPORT- PROFESSIONAL: OTHER ( R499 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Award ID (Mod#):
W81XWH12C0144 ( P00002 ) (View) Award Type: DEFINITIVE CONTRACT
Vendor Name: MAPP BIOPHARMACEUTICAL, INC. Contracting Agency: DEPT OF THE ARMY
Date Signed: December 19, 2013 Action Obligation: $0
Referenced IDV: Contracting Office: W4PZ USA MED RSCH ACQUIS ACT
NAICS (Code): RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY ( 541711 ) PSC (Code): SUPPORT- PROFESSIONAL: OTHER ( R499 )
Vendor City: SAN DIEGO Vendor DUNS: 137551797
Vendor State: CA Vendor ZIP: 921212740
Global Vendor Name: MAPP BIOPHARMACEUTICAL INC. Global DUNS Number: 137551797

Pictures (click to insert)





\| Next Page >>